These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 12411788)

  • 1. Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility.
    Monnier N; Krivosic-Horber R; Payen JF; Kozak-Ribbens G; Nivoche Y; Adnet P; Reyford H; Lunardi J
    Anesthesiology; 2002 Nov; 97(5):1067-74. PubMed ID: 12411788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
    Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
    Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred.
    Lynch PJ; Krivosic-Horber R; Reyford H; Monnier N; Quane K; Adnet P; Haudecoeur G; Krivosic I; McCarthy T; Lunardi J
    Anesthesiology; 1997 Mar; 86(3):620-6. PubMed ID: 9066328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
    Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
    Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patients with malignant hyperthermia demonstrate an altered calcium control mechanism in B lymphocytes.
    Sei Y; Brandom BW; Bina S; Hosoi E; Gallagher KL; Wyre HW; Pudimat PA; Holman SJ; Venzon DJ; Daly JW; Muldoon S
    Anesthesiology; 2002 Nov; 97(5):1052-8. PubMed ID: 12411786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
    Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
    Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using exome data to identify malignant hyperthermia susceptibility mutations.
    Gonsalves SG; Ng D; Johnston JJ; Teer JK; Stenson PD; Cooper DN; Mullikin JC; Biesecker LG;
    Anesthesiology; 2013 Nov; 119(5):1043-53. PubMed ID: 24195946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant hyperthermia susceptibility, an autosomal dominant disorder?
    Fagerlund TH; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Jun; 51(6):365-9. PubMed ID: 9237497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ryanodine receptor type 1 gene variants in the malignant hyperthermia-susceptible population of the United States.
    Brandom BW; Bina S; Wong CA; Wallace T; Visoiu M; Isackson PJ; Vladutiu GD; Sambuughin N; Muldoon SM
    Anesth Analg; 2013 May; 116(5):1078-1086. PubMed ID: 23558838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Modern diagnostic approaches to malignant hyperthermia susceptibility].
    Kazantseva AA; Lebedinskiĭ KM
    Anesteziol Reanimatol; 2014; 59(4):64-8. PubMed ID: 25549489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An autosomal dominant congenital myopathy with cores and rods is associated with a neomutation in the RYR1 gene encoding the skeletal muscle ryanodine receptor.
    Monnier N; Romero NB; Lerale J; Nivoche Y; Qi D; MacLennan DH; Fardeau M; Lunardi J
    Hum Mol Genet; 2000 Nov; 9(18):2599-608. PubMed ID: 11063719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing the number of diagnostic mutations in malignant hyperthermia.
    Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
    Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families.
    Robinson R; Curran JL; Hall WJ; Halsall PJ; Hopkins PM; Markham AF; Stewart AD; West SP; Ellis FR
    J Med Genet; 1998 Mar; 35(3):196-201. PubMed ID: 9541102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for genetic heterogeneity of malignant hyperthermia susceptibility.
    Deufel T; Golla A; Iles D; Meindl A; Meitinger T; Schindelhauer D; DeVries A; Pongratz D; MacLennan DH; Johnson KJ
    Am J Hum Genet; 1992 Jun; 50(6):1151-61. PubMed ID: 1598899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of a positive malignant hyperthermia (MH) disposition without the in vitro contracture test in families carrying the RYR1 Arg614Cys mutation.
    Rueffert H; Olthoff D; Deutrich C; Froster UG
    Clin Genet; 2001 Aug; 60(2):117-24. PubMed ID: 11553045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.